FDA approved Rasonque for metastatic PDAC, while Kras and Incyte also developed PDAC inhibitors and Incyte received a CMS settlement benefit.
2 reports, 1 independent
Updated Aug 28
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA approved Rasonque for metastatic PDAC, while Kras and Incyte also developed PDAC inhibitors and Incyte received a CMS settlement benefit.